Clinical Trial: A Study of AWT020 in Participants With Advanced Solid Tumors

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07822919) titled 'A Study of AWT020 in Participants With Advanced Solid Tumors' on Sept. 02.

Brief Summary: This study is aimed at establishing the MTD and/or the RP2D for AWT020 monotherapy and to provide safety, tolerability, efficacy, PK, immunogenicity characteristics of AWT020.

Study Start Date: Sept. 11

Study Type: INTERVENTIONAL

Condition: Advanced Cancers (Solid Tumors)

Intervention: BIOLOGICAL: AWT020

Participants receiving AWT020 once every three weeks at designated dose levels

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Anwita Biosciences

Published by HT Digital Content Services with permission from Health Daily Digest....